Using medicare data for comparative effectiveness research: Opportunities and challenges

American Journal of Managed Care

Volumn 17, Issue 7, 2011, Pages 489-496

  Fung, Vicki ^a   Brand, Richard J ^b   Newhouse, Joseph P ^c,d,e   Hsu, John ^c,f  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; LOWEST INCOME GROUP; MEDICAL RESEARCH; MEDICARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ARTICLE; COMPARATIVE EFFECTIVENESS; ECONOMICS; INSURANCE; METHODOLOGY; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; INSURANCE BENEFITS; MEDICARE; MEDICARE PART D; TREATMENT OUTCOME; UNITED STATES;

EID: 84856022977     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. The Kaiser Family Foundation. The Medicare Prescription Drug Benefit: Fact Sheet. Washington, DC: The Henry J. Kaiser Family Foundation; October 2010. http://www.kff.org/medicare/7044.cfm. Accessed June 8, 2011.
2. McNeil BJ. Shattuck Lecture-hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345(22):1612-1620. (Pubitemid 33126842)
3. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268(11):1417-1422.
4. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708-713. (Pubitemid 33010364)
5. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-1632. (Pubitemid 37430387)
6. Luce BR, Paramore LC, Parasuraman B, Liljas B, de Lissovoy G. Can managed care organizations partner with manufacturers for comparative effectiveness research? Am J Manag Care. 2008;14(3):149-156. (Pubitemid 351367358)
7. The Kaiser Family Foundation. The Medicare Prescription Drug Benefit: Fact Sheet. Washington, DC: The Henry J. Kaiser Family Foundation; November 2009. http://www.kff.org/medicare/7044.cfm. Accessed June 8, 2011.
8. Medicare Payment Advisory Commission (MedPAC). Report to the Congress: Medicare Payment Policy. www.medpac.gov/documents/mar10-entirereport.pdf. Published March 2010. Accessed June 8, 2011.
9. Research Data Assistance Center. Requesting CMS data. http://www.resdac.org/Medicare/requesting-data.asp. Published March 9, 2011. Accessed March 22, 2011.
10. Research Data Assistance Center. Medicare data documentation. http://www.resdac.org/ddvh/index.asp. Accessed June 10, 2010.
11. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116. (Pubitemid 27089212)
12. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359. (Pubitemid 43801280)
13. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care. 2007;45(10 suppl 2):S58-S65.
14. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report - Part II. Value Health. 2009;12(8):1053-1061.
15. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? analysis using instrumental variables. JAMA. 1994;272(11):859-866. (Pubitemid 24282095)
16. McClellan M, Newhouse JP. The marginal costs and benefits of medical technology: a panel instrumental variables approach. J Econometrics. 1997;77(1):39-64. (Pubitemid 127381045)
17. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17-34. (Pubitemid 28279922)
18. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med. 1990;89(5):630-638. (Pubitemid 20384321)
19. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research: interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999;319(7205):312-315. (Pubitemid 29353952)
20. Yusuf S, Held P, Teo KK, Toretsky ER. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med. 1990;9(1-2):73-83.
21. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care. 2007;45(10 suppl 2):S143-S148.
22. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
23. McCormack LA, Fox PD, Rice T, Graham ML. Medigap reform legislation of 1990: have the objectives been met? Health Care Financ Rev. 1996;18(1):157-174. (Pubitemid 27074348)
24. Riley GF, Levy JM, Montgomery MA. Adverse selection in the Medicare prescription drug program. Health Aff (Millwood). 2009;28(6):1826-1837.
25. Neuman P, Cubanski J. Medicare Part D update - lessons learned and unfinished business. N Engl J Med. 2009;361(4):406-414.
26. Wennberg JE, Freeman JL, Shelton RM, Bubolz TA. Hospital use and mortality among Medicare beneficiaries in Boston and New Haven. N Engl J Med. 1989;321(17):1168-1173. (Pubitemid 19255813)
27. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, P I: the content, quality, and accessibility of care. Ann Intern Med. 2003;138(4):273-287. (Pubitemid 36205924)
28. Soumerai S, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072-1077.
29. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268-275.
30. Wharam JF, Daniels N. Toward evidence-based policy making and standardized assessment of health policy reform. JAMA. 2007;298(6):676-679. (Pubitemid 47236420)
31. The Kaiser Family Foundation. Medicare Advantage Fact Sheet. Washington, DC: The Henry J. Kaiser Family Foundation; September 2010. http://www.kff.org/ medicare/upload/2052-14.pdf. Accessed June 23, 2011.
32. Institute of Medicine. 100 Initial Priority Topics for Comparative Effectiveness Research. http://www.iom.edu/~/media/Files/Report%20Files/2009/ ComparativeEffectivenessResearchPriorities/Stand%20 Alone%20List%20of%20100%20CER%20Priorities%20-%20for%20web.ashx. Accessed June 10, 2010.
33. Federal Business Opportunities. CER-Public Use Data Pilot Project. June 3, 2010. https://www.fbo.gov/index?s=opportunity&mode=form &id=4841b0bcb3a66d848e5f9bca325d8083&tab=core&-cview=0. Accessed September 7, 2010.
34. IMPAQ International LLC. Quantitative data analysis projects. Featured project: Recovery - Comparative Effectiveness Research (CER) Public Use Data Pilot Project. http://www.impaqint.com/projectshowcase/ quantitative-data- analysis-projects/default.html. Accessed September 7, 2010.